SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2019.12.03 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) - HTML (w)

2019.11.22 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) - HTML (w)

2019.11.21 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder - HTML (w)

2019.11.06 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis - HTML (w)

2019.11.04 | 22:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 - HTML (w)

2019.10.30 | 12:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis - HTML (w)

2019.10.22 | 12:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies - HTML (w)

2019.10.22 | Periodic information / 3rd Quarter Information

English version PDF Mail

puce Biogen Idec Inc : Third quarter 2019 - PDF (513Kb)

2019.10.21 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week - HTML (w)

2019.10.02 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders - HTML (w)

2019.10.01 | 14:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Leadership Update - HTML (w)

2019.09.23 | 09:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding - HTML (w)

2019.09.18 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients - HTML (w)

2019.09.17 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index - HTML (w)

2019.09.12 | 11:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 / Doc nb : 82